68 related articles for article (PubMed ID: 22088438)
1. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells.
Yoon H; Min JK; Lee DG; Kim DG; Koh SS; Hong HJ
Cancer Lett; 2012 Mar; 316(1):70-6. PubMed ID: 22088438
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2.
Yoon H; Min JK; Lee JW; Kim DG; Hong HJ
Biochem Biophys Res Commun; 2011 Feb; 405(3):333-7. PubMed ID: 21130731
[TBL] [Abstract][Full Text] [Related]
3. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo.
Rajput A; Koterba AP; Kreisberg JI; Foster JM; Willson JK; Brattain MG
Cancer Res; 2007 Jan; 67(2):665-73. PubMed ID: 17234777
[TBL] [Abstract][Full Text] [Related]
4. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
Kim SH; Song YC; Kim SH; Jo H; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
[TBL] [Abstract][Full Text] [Related]
5. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
6. The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer.
Oh M; Lee JY; Shin DH; Park JH; Oian T; Kim HJ; Cho SD; Oh SH; Min YK; Kong G
Cancer Sci; 2011 Mar; 102(3):597-604. PubMed ID: 21205071
[TBL] [Abstract][Full Text] [Related]
7. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
[TBL] [Abstract][Full Text] [Related]
8. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
[TBL] [Abstract][Full Text] [Related]
9. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.
Okano J; Nagahara T; Matsumoto K; Murawaki Y
Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):543-51. PubMed ID: 18346049
[TBL] [Abstract][Full Text] [Related]
10. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model.
Chan JK; Pham H; You XJ; Cloven NG; Burger RA; Rose GS; Van Nostrand K; Korc M; Disaia PJ; Fan H
Cancer Res; 2005 Apr; 65(8):3243-8. PubMed ID: 15833856
[TBL] [Abstract][Full Text] [Related]
11. Akt expression may predict favorable prognosis in cholangiocarcinoma.
Javle MM; Yu J; Khoury T; Chadha KS; Iyer RV; Foster J; Kuvshinoff BW; Gibbs JF; Geradts J; Black JD; Brattain MG
J Gastroenterol Hepatol; 2006 Nov; 21(11):1744-51. PubMed ID: 16984600
[TBL] [Abstract][Full Text] [Related]
12. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract][Full Text] [Related]
13. The cell adhesion molecule L1 promotes gallbladder carcinoma progression in vitro and in vivo.
Jung J; Son YS; Park H; Jeon SK; Lee JW; Choi SY; Kim JM; Kwon YG; Hong HJ; Min JK
Oncol Rep; 2011 Apr; 25(4):945-52. PubMed ID: 21318226
[TBL] [Abstract][Full Text] [Related]
14. A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model.
Lee ES; Jeong MS; Singh R; Jung J; Yoon H; Min JK; Kim KH; Hong HJ
Exp Mol Med; 2012 Apr; 44(4):293-302. PubMed ID: 22248567
[TBL] [Abstract][Full Text] [Related]
15. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
16. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.
Martinez-Becerra P; Vaquero J; Romero MR; Lozano E; Anadon C; Macias RI; Serrano MA; Grañé-Boladeras N; Muñoz-Bellvis L; Alvarez L; Sangro B; Pastor-Anglada M; Marin JJ
Mol Pharm; 2012 Jun; 9(6):1693-704. PubMed ID: 22524153
[TBL] [Abstract][Full Text] [Related]
17. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.
Yang B; Tong R; Liu H; Wu J; Chen D; Xue Z; Ding C; Zhou L; Xie H; Wu J; Zheng S
Int J Oncol; 2018 Apr; 52(4):1235-1245. PubMed ID: 29532867
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway.
Zhang LY; Shen ZX; Guo L
Cancer Invest; 2022 Apr; 40(4):313-324. PubMed ID: 35040385
[TBL] [Abstract][Full Text] [Related]
19. L1 increases adhesion-mediated proliferation and chemoresistance of retinoblastoma.
Jo DH; Lee K; Kim JH; Jun HO; Kim Y; Cho YL; Yu YS; Min JK; Kim JH
Oncotarget; 2017 Feb; 8(9):15441-15452. PubMed ID: 28061460
[TBL] [Abstract][Full Text] [Related]
20. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
Peng H; Zhang Q; Li J; Zhang N; Hua Y; Xu L; Deng Y; Lai J; Peng Z; Peng B; Chen M; Peng S; Kuang M
Oncotarget; 2016 Mar; 7(13):17220-9. PubMed ID: 26967384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
